학술논문
Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients.
Document Type
Journal Article
Author
Source
Subject
*INSULIN
*TYPE 2 diabetes
*DRUGS
*GENE expression
*MUSCLES
*FATTY acids
*ADIPOSE tissues
*BENZOPYRANS
*BIOCHEMISTRY
*BIOLOGICAL transport
*CLINICAL trials
*COMPARATIVE studies
*ENERGY metabolism
*HYPOGLYCEMIC agents
*PHENOMENOLOGY
*RESEARCH methodology
*MEDICAL cooperation
*OXIDATION-reduction reaction
*RESEARCH
*EVALUATION research
*RANDOMIZED controlled trials
*PHARMACODYNAMICS
*THIAZOLIDINEDIONES
*THERAPEUTICS
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0012-1797
Abstract
Thiazolidinediones (TZDs) are a new class of insulin-sensitizing drugs. To explore how and in which tissues they improve insulin action, we obtained fat and muscle biopsies from eight patients with type 2 diabetes before and 2 months after treatment with rosiglitazone (n = 5) or troglitazone (n = 3). TZD treatment was associated with a coordinated upregulation in the expression of genes and synthesis of proteins involved in fatty acid uptake, binding, beta-oxidation and electron transport, and oxidative phosphorylation in subcutaneous fat but not in skeletal muscle. These changes were accompanied by a 13% increase in total body fat oxidation, a 20% decrease in plasma free fatty acid levels, and a 46% increase in insulin-stimulated glucose uptake. We conclude that TZDs induced a coordinated stimulation of fatty acid uptake, oxidation, and oxidative phosphorylation in fat of diabetic patients and thus may have corrected, at least partially, a recently recognized defect in patients with type 2 diabetes consisting of reduced expression of genes related to oxidative metabolism and mitochondrial function. [ABSTRACT FROM AUTHOR]